中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

慢加急性肝衰竭预后标志物的研究现状

李健 杜亚秋 李德钊 季慧范 张成港 刘庆夏 郭晓林

李健, 杜亚秋, 李德钊, 等. 慢加急性肝衰竭预后标志物的研究现状[J]. 临床肝胆病杂志, 2021, 37(11): 2701-2705. DOI: 10.3969/j.issn.1001-5256.2021.11.047
引用本文: 李健, 杜亚秋, 李德钊, 等. 慢加急性肝衰竭预后标志物的研究现状[J]. 临床肝胆病杂志, 2021, 37(11): 2701-2705. DOI: 10.3969/j.issn.1001-5256.2021.11.047
LI J, DU YQ, LI DZ, et al. Current status of research on the prognostic markers for acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(11): 2701-2705. DOI: 10.3969/j.issn.1001-5256.2021.11.047
Citation: LI J, DU YQ, LI DZ, et al. Current status of research on the prognostic markers for acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(11): 2701-2705. DOI: 10.3969/j.issn.1001-5256.2021.11.047

慢加急性肝衰竭预后标志物的研究现状

DOI: 10.3969/j.issn.1001-5256.2021.11.047
基金项目: 

国家重点研发计划“精准医学研究”专项 2017YFC0908104

详细信息
    通讯作者:

    郭晓林,guoxiaolin0324@126.com

  • 中图分类号: R575.3

Current status of research on the prognostic markers for acute-on-chronic liver failure

Research funding: 

National Key Research Plan "Precision Medicine Research" Key Project 2017YFC0908104

  • 摘要: 慢加急性肝衰竭是一种以多器官功能衰竭、短期病死率高为主要特点的综合病症,是重症肝病领域的研究热点,故早期和准确的进行危险分层、及时加强干预,对切实改善预后具有重要意义。归纳总结了近年来涌现的评估ACLF患者预后的血清生物学标志物,认为新型血清标志物在ACLF患者的预后评估上具有重要指导意义。

     

  • [1] MOREAU R, JALAN R, GINES P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013, 144(7): 1426-1437, 37 e1-9. DOI: 10.1053/j.gastro.
    [2] SARIN SK, KEDARISETTY CK, ABBAS Z, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014[J]. Hepatol Int, 2014, 8(4): 453-471. DOI: 10.1007/s12072-014-9580-2.
    [3] WU T, LI J, SHAO L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. Gut, 2018, 67(12): 2181-2191. DOI: 10.1136/gutjnl-2017-314641.
    [4] ABBAS Z, SHAZI L. Pattern and profile of chronic liver disease in acute on chronic liver failure[J]. Hepatol Int, 2015, 9(3): 366-372. DOI: 10.1007/s12072-015-9627-z.
    [5] SARIN SK, CHOUDHURY A. Acute-on-chronic liver failure: terminology, mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(3): 131-149. DOI: 10.1038/nrgastro.2015.219.
    [6] LI J, LI J. Similarities and differences in pathogenesis of acute-on-chronic liver failure between the East and West[J]. Chin J Infect Dis, 2019, 37(9): 513-517. DOI: 10.3760/cma.j.issn.1000-6680.2019.09.001.

    李君, 李江. 慢加急性肝衰竭发病机制的东西方异同[J]. 中华传染病杂志, 2019, 37(9): 513-517. DOI: 10.3760/cma.j.issn.1000-6680.2019.09.001.
    [7] WU J, LIN S, WAN B, et al. Pyroptosis in liver disease: New insights into disease mechanisms[J]. Aging Dis, 2019, 10(5): 1094-1098. DOI: 10.14336/AD.2019.0116.
    [8] WU D, ZHANG S, XIE Z, et al. Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure[J]. J Clin Invest, 2020, 130(4): 2069-2080. DOI: 10.1172/JCI130197.
    [9] WU W, LI J, CHEN F, et al. Circulating Th17 cells frequency is associated with the disease progression in HBV infected patients[J]. J Gastroenterol Hepatol, 2010, 25(4): 750-757. DOI: 10.1111/j.1440-1746.2009.06154.x.
    [10] LEEPW, SMITH AJ, YANG Y, et al. IL-23R-activated STAT3/STAT4 is essential for Th1/Th17-mediated CNS autoimmunity[J]. JCI Insight, 2017, 2(17): e91663. DOI: 10.1172/jci.insight.91663.
    [11] YAMAGUCHI R, SAKAMOTO A, YAMAMOTO T, et al. Differential regulation of IL-23 production in M1 macrophages by TIR8SIGIRR through TLR4- or TLR78-medi ated signaling[J]. Cytokine, 2017, 99: 310-315. DOI: 10.1016/j.cyto.2017.08.014.
    [12] BAO SX, ZHENG JM, LI N, et al. Role of interleukin-23 in monocyte-derived dendritic cells of HBV-related acute-on-chronic liver failure and its correlation with the severity of liver damage[J]. Clin Res Hepatol Gastroenterol, 2017, 41(2): 147-155. DOI: 10.1016/j.clinre.2016.10.005.
    [13] WANG Q, ZHOU J, ZHANG B, et al. Hepatitis B virus induces IL-23 production in antigen presenting cells and causes liver damage via the IL-23/IL-17 axis[J]. PLoS Pathog, 2013, 9(6): e1003410. DOI: 10.1371/journal.ppat.1003410.
    [14] KHANAM A, TREHANPATI N, SARIN SK. Increased interleukin-23 receptor (IL-23R) expression is associated with disease severity in acute-on-chronic liver failure[J]. Liver Int, 2019, 39(6): 1062-70. DOI: 10.1111/liv.14015.
    [15] MICHALOPOULOS GK. Hepatostat: Liver regeneration and normal liver tissue maintenance[J]. Hepatology, 2017, 65(4): 1384-1392. DOI: 10.1002/hep.28988.
    [16] CLARIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
    [17] SCHMIDT-ARRAS D, ROSE-JOHN S. IL-6 pathway in the liver: From physiopathology to therapy[J]. J Hepatol, 2016, 64(6): 1403-1415. DOI: 10.1016/j.jhep.2016.02.004.
    [18] ZHOU C, ZHANG N, HE TT, et al. High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure[J]. World J Gastroenterol, 2020, 26(30): 4479-4488. DOI: 10.3748/wjg.v26.i30.4479.
    [19] SHUI JW, STEINBERG MW, KRONENBERG M. Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling[J]. J Leukoc Biol, 2011, 89(4): 517-523. DOI: 10.1189/jlb.0910528.
    [20] SHEIKH M, ENGELMANN C, HABTESION A, et al. Inhibition of toll-like receptor 4 using TAK-242 is a novel therapy for prevention and treatment of acute-on-chronic liver failure[J]. J Hepatol, 2019, 70(1): e64-e65. DOI: 10.1016/S0618-8278(19)30113-6.
    [21] HATO T, GOYAL L, GRETEN TF, et al. Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions[J]. Hepatology, 2014, 60(5): 1776-1782. DOI: 10.1002/hep.27246.
    [22] ZHANG Z, ZHANG JY, WHERRY EJ, et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B[J]. Gastroenterology, 2008, 134(7): 1938-1949, e1-3. DOI: 10.1053/j.gastro.2008.03.037.
    [23] KAO C, OESTREICH KJ, PALEY MA, et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection[J]. Nat Immunol, 2011, 12(7): 663-671. DOI: 10.1038/ni.2046.
    [24] CAO D, XU H, GUO, et al. Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure[J]. Inflammation, 2013, 36(1): 110-120. DOI: 10.1007/s10753-012-9525-7.
    [25] WENCESLAU CF, MCCARTHY CG, SZASZ T, et al. Mitochondrial damage-associated molecular patterns and vascular function[J]. Eur Heart J, 2014, 35(18): 1172-1177. DOI: 10.1093/eurheartj/ehu047.
    [26] CAI J, HAN T, NIE C, et al. Biomarkers of oxidation stress, inflammation, necrosis and apoptosis are associated with hepatitis B-related acute-on-chronic liver failure[J]. Clin Res Hepatol Gastroenterol, 2016, 40(1): 41-50. DOI: 10.1016/j.clinre.2015.06.009.
    [27] YAN HF, XU BX, LI XO, et al. Effects of lipopolysaccharide on proliferation, secretion and ultrastructure of kupffer cells in liver[J]. Med J Chin People's Liberation Army, 2017, 29(10): 1-4. DOI: 10.3969/j.issn.2095-140X.2017.10.001.

    闫洪锋, 徐冰心, 李晓殴, 等. 脂多糖对肝脏Kupffer细胞增殖和分泌功能及超微结构的影响[J]. 解放军医药杂志, 2017, 29(10): 1-4. DOI: 10.3969/j.issn.2095-140X.2017.10.001.
    [28] NI X, EPSHTEIN Y, CHEN W, et al. Interaction of integrin β4 with S1P receptors in S1P- and HGF-induced endothelial barrier enhancement[J]. J Cell Biochem, 2014, 115(6): 1187-1195. DOI: 10.1002/jcb.24770.
    [29] INCE C, MAYEUX, PR, NGUYEN T, et al. The endothelium in sepsis[J]. Shock, 2016, 45(3): 259-270. DOI: 10.1097/SHK.0000000000000473.
    [30] MUCKE VT, MARIA SCHWARZKOPF K, THOMAS D, et al. Serum sphingosine-1-phosphate is decreased in patients with acute-on-chronic liver failure and predicts early mortality[J]. Hepatol Commun, 2020, 4(10): 1477-1486. DOI: 10.1002/hep4.1561.
    [31] CAO Z, LI F, XIANG X, et al. Circulating cell death biomarker: Good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure[J]. Sci Rep, 2015, 5: 14240. DOI: 10.1038/srep14240.
    [32] KAKISAKA K, KATAOKA K, ONODERA M, et al. Alpha-fetoprotein: A biomarker for the recruitment of progenitor cells in the liver in patients with acute liver injury or failure[J]. Hepatol Res, 2015, 45(10): e12-20. DOI: 10.1111/hepr.12448.
    [33] WANG X, SHEN C, YANG J, et al. Alpha-fetoprotein as a predictive marker for patients with hepatitis B-related acute-on-chronic liver failure[J]. Can J Gastroenterol Hepatol, 2018, 2018: 1232785. DOI: 10.1155/2018/1232785.
    [34] SHIMIZU M, HARA A, OKUNO M, et al. Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: Impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis[J]. Hepatology, 2001, 33(3): 569-576. DOI: 10.1053/jhep.2001.22650.
    [35] BEZERRA JA, BUGGE TH, MELIN-ALDANA H, et al. Plasminogen deficiency leads to impaired remodeling after a toxic injury to the liver[J]. Proc Natl Acad Aci USA, 1999, 96(26): 15143-15148. DOI: 10.1073/pnas.96.26.15143.
    [36] RENSEN SS, SLAATS Y, DRIESSEN A, et al. Activation of the complement system in human nonalcoholic fatty liver disease[J]. Hepatology, 2009, 50(6): 1809-1817. DOI: 10.1002/hep.23228
    [37] LI Q, LU Q, ZHU MQ, et al. Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure[J]. BMC Gastroenterol, 2020, 20(1): 106. DOI: 10.1186/s12876-020-01258-3.
    [38] BOLTJES A, MOVITA D, BOONSTRA A, et al. The role of Kupffer cells in hepatitis B and hepatitis C virus infections[J]. J Hepatol, 2014, 61(3): 660-671. DOI: 10.1016/j.jhep.2014.04.026.
    [39] RODGAARD-HANSEN S, RAFIQUE A, WEIS N, et al. Increased concentrations of the soluble mannose receptor in serum from patients with pneumococcal bacteraemia, and prediction of survival[J]. Infect Dis (Lond), 2015, 47(4): 203-208. DOI: 10.3109/00365548.2014.984321.
    [40] ANDERSEN ES, RODGAARD-HANSEN S, MOESSNER B, et al. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: A pilot study[J]. Eur J Clin Microbiol Infect Dis, 2014, 33(1): 117-122. DOI: 10.1007/s10096-013-1936-3.
    [41] GRONBAEK H, RODGAARD-HANSEN S, AAGAARD NK, et al. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF)[J]. J Hepatol, 2016, 64(4): 813-822. DOI: 10.1016/j.jhep.2015.11.021.
    [42] ARIZA X, GRAUPERA I, COLL M, et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis[J]. J Hepatol, 2016, 65(1): 57-65. DOI: 10.1016/j.jhep.2016.03.002.
    [43] AFSAR B. Pathophysiology of copeptin in kidney disease and hypertension[J]. Clin Hypertens, 2017, 23: 13. DOI: 10.1186/s40885-017-0068-y.
    [44] BARRETO R, ELIA C, SOLA E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections[J]. J Hepatol, 2014, 61(1): 35-42. DOI: 10.1016/j.jhep.2014.02.023.
    [45] LU J, LIN L, YE C, et al. Serum NGAL is superior to cystatin C in predicting the prognosis of acute-on-chronic liver failure[J]. Ann Hepatol, 2019, 18(1): 155-164. DOI: 10.5604/01.3001.0012.7907.
    [46] CHEN XP, SU S, ZHOU PC, et al. MiR-494 alleviates hepatic ischemia-reperfusion injury in rats by activating PI3K/AKT signaling pathway[J]. Ogran Transplantation, 2019, 10(3): 295-301. DOI: 10.3969/j.issn.1674-7445.2019.03.012.

    陈鑫培, 苏松, 周鹏程, 等. MiR-494通过激活PI3K/AKT通路减轻大鼠肝缺血——再灌注损伤[J]. 器官移植, 2019, 10(3): 295-301. DOI: 10.3969/j.issn.1674-7445.2019.03.012.
    [47] CHENG HR, KAO JH, WU HL, et al. Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection[J]. Hepatol Int, 2015, 9(1): 35-42. DOI: 10.1007/s12072-014-9591-z.
    [48] WESESLINDTNER L, MACHELEIDT I, EISCHEID H, et al. Micro RNAs miR-106a, miR-122 and miR-197 are increased in severe acuteviral hepatitis with coagulopathy[J]. Liver Int, 2016, 36(3): 353-360. DOI: 10.1111/liv.12961.
    [49] WEN Y, PENG SF, FU L, et al. Serum levels of miRNA in patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(2): 126-132. DOI: 10.1016/j.hbpd.2018.03.004.
  • 加载中
计量
  • 文章访问数:  74
  • HTML全文浏览量:  33
  • PDF下载量:  24
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-03-26
  • 修回日期:  2021-04-13
  • 网络出版日期:  2021-11-16
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回